Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Erbitux Cetuximab Metastatic Colorectal Cancer Do not reimburse Complete
Erbitux Cetuximab Cancelled
Erelzi Etanercept Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Erivedge Vismodegib Basal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide metastatic castration-sensitive prostate cancer (mCSPC) Reimburse with clinical criteria and/or conditions Complete
Esbriet Pirfenidone Idiopathic pulmonary fibrosis List with criteria/condition Complete
Esbriet Pirfenidone Idiopathic pulmonary fibrosis Do not list Complete
Eucrisa crisaborole atopic dermatitis Do not reimburse Complete
Evenity romosozumab Osteoporosis, postmenopausal women Reimburse with clinical criteria and/or conditions Complete